|Bid||250.03 x 13700|
|Ask||250.16 x 21700|
|Day's Range||242.00 - 251.16|
|52 Week Range||242.00 - 332.68|
|Beta (5Y Monthly)||0.10|
|PE Ratio (TTM)||42.79|
|Earnings Date||Feb 18, 2021|
|Forward Dividend & Yield||2.81 (1.14%)|
|Ex-Dividend Date||Mar 04, 2021|
|1y Target Est||151.95|
Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication for people two years of age and older.1 FLUCELVAX QUADRIVALENT was previously FDA-approved for use in persons four years of age and older. FLUCELVAX QUADRIVALENT will be available as a 0.5ml intramuscular (IM) vaccine per dose for the 2021/22 U.S. influenza season.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CSL Limited ( ASX:CSL...
With its stock down 6.4% over the past three months, it is easy to disregard CSL (ASX:CSL). However, a closer look at...